TickerKhojComparison · NSE · data 2026-11-03
Hester Biosciences Limited vs Syncom Formulation (India) Ltd.
In plain words
Size: Hester Biosciences Limited is about 1.1 times the market value of Syncom Formulation (India) Ltd..
Valuation (P/E): Syncom Formulation (India) Ltd. 21 vs Hester Biosciences Limited 14.1.
Return on equity: Syncom Formulation (India) Ltd. 20.2% vs Hester Biosciences Limited 16.5%.
Profit growth over 3 years: Syncom Formulation (India) Ltd. 56.2% a year vs Hester Biosciences Limited 27.8% a year.
Debt to equity: Hester Biosciences Limited 0.54 vs Syncom Formulation (India) Ltd. 0.
Differences in the numbers, not a recommendation of either stock.
Side by side
19 metrics shown
| HESTERBIO | SYNCOMF | |
|---|---|---|
| Price | ₹2,262.1 | ₹19.07 |
| Market cap | ₹1,931 cr | ₹1,807 cr |
| P/E | 14.1 | 21 |
| P/B | — | — |
| ROE | 16.5% | 20.2% |
| ROCE | 13.0% | 16.3% |
| Debt / equity | 0.54 | 0 |
| Operating margin | 19.9% | 16.3% |
| Dividend yield | 0.48% | 0.52% |
| Sales growth, 3 years (yearly) | 7.7% | 29.4% |
| Profit growth, 3 years (yearly) | 27.8% | 56.2% |
| 1-year return | 41.1% | 16.5% |
| Revenue, last 12 months | ₹326 cr | ₹498 cr |
| Net profit, last 12 months | ₹136 cr | ₹86 cr |
| Latest quarter | Jun 2026 | Jun 2026 |
| Quarter net profit | ₹97 cr | ₹25 cr |
| Quarter profit vs a year earlier | +489.9% | +57.8% |
| Promoter holding | 44.28% | 50.57% |
| Health check | Strong (8.4/10) | Strong (8.4/10) |
Common questions
Which has a higher P/E, Hester Biosciences Limited or Syncom Formulation (India) Ltd.?
Syncom Formulation (India) Ltd. trades at the higher P/E (21 against 14.1). A higher P/E means the market pays more for each rupee of past earnings; on its own it does not say which is better.
Which earns a higher return on equity?
Syncom Formulation (India) Ltd. (20.2% against 16.5%).
Which carries more debt?
Hester Biosciences Limited has the higher debt-to-equity ratio (0.54 against 0).